You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 17, 2025

CLINICAL TRIALS PROFILE FOR ISONIAZID; RIFAMPIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Isoniazid; Rifampin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000636 ↗ Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb). Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.
NCT00000638 ↗ Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection Completed Hoechst Marion Roussel N/A 1969-12-31 To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with both HIV and latent (inactive) Mycobacterium tuberculosis. Current guidelines from the American Thoracic Society and the Centers for Disease Control recommend 6 to 12 months of INH for PPD (purified protein derivative)-positive individuals. Although the effectiveness of this treatment is not known for HIV-infected individuals, several studies using INH to prevent tuberculosis in presumably normal hosts have shown 60 to 80 percent effectiveness. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to tuberculosis organisms being resistant to INH. A two-month preventive treatment plan should help in increasing compliance. In addition, the use of two drugs (rifampin / pyrazinamide) may help overcome problems with drug resistance. If this study shows equal or greater effectiveness of the two-month rifampin / pyrazinamide treatment, it could alter the approach to tuberculosis prevention for both HIV-positive and HIV-negative individuals.
NCT00000638 ↗ Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection Completed Lederle Laboratories N/A 1969-12-31 To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with both HIV and latent (inactive) Mycobacterium tuberculosis. Current guidelines from the American Thoracic Society and the Centers for Disease Control recommend 6 to 12 months of INH for PPD (purified protein derivative)-positive individuals. Although the effectiveness of this treatment is not known for HIV-infected individuals, several studies using INH to prevent tuberculosis in presumably normal hosts have shown 60 to 80 percent effectiveness. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to tuberculosis organisms being resistant to INH. A two-month preventive treatment plan should help in increasing compliance. In addition, the use of two drugs (rifampin / pyrazinamide) may help overcome problems with drug resistance. If this study shows equal or greater effectiveness of the two-month rifampin / pyrazinamide treatment, it could alter the approach to tuberculosis prevention for both HIV-positive and HIV-negative individuals.
NCT00000638 ↗ Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with both HIV and latent (inactive) Mycobacterium tuberculosis. Current guidelines from the American Thoracic Society and the Centers for Disease Control recommend 6 to 12 months of INH for PPD (purified protein derivative)-positive individuals. Although the effectiveness of this treatment is not known for HIV-infected individuals, several studies using INH to prevent tuberculosis in presumably normal hosts have shown 60 to 80 percent effectiveness. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to tuberculosis organisms being resistant to INH. A two-month preventive treatment plan should help in increasing compliance. In addition, the use of two drugs (rifampin / pyrazinamide) may help overcome problems with drug resistance. If this study shows equal or greater effectiveness of the two-month rifampin / pyrazinamide treatment, it could alter the approach to tuberculosis prevention for both HIV-positive and HIV-negative individuals.
NCT00000796 ↗ A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDR Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain. Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
NCT00000950 ↗ Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metabolized in the body.
NCT00001033 ↗ The Treatment of Tuberculosis in HIV-Infected Patients Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1969-12-31 PER 5/30/95 AMENDMENT: To compare the combined rate of failure during therapy and relapse after therapy between two durations of intermittent therapy (6 versus 9 months) for the treatment of pulmonary tuberculosis (TB) in HIV-infected patients. To compare toxicity, survival, and development of resistance in these two regimens. ORIGINAL: To compare the efficacy and safety of induction and continuation therapies for the treatment of pulmonary TB in HIV-infected patients who are either from areas with known high rates of resistance to one or more anti-TB drugs or from areas where TB is expected to be susceptible to commonly used anti-TB drugs. PER 5/30/95 AMENDMENT: In HIV-negative patients, intermittent anti-TB therapy has been shown to be as effective as daily therapy, but the optimal duration of therapy in HIV-infected patients has not been established. ORIGINAL: In some areas of the country, resistance to one or more of the drugs commonly used to treat TB has emerged. Thus, the need to test regimens containing a new drug exists. Furthermore, the optimal duration of anti-TB therapy for HIV-infected patients with TB needs to be determined.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Isoniazid; Rifampin

Condition Name

Condition Name for Isoniazid; Rifampin
Intervention Trials
Tuberculosis 28
HIV Infections 8
Tuberculosis, Pulmonary 7
Pulmonary Tuberculosis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Isoniazid; Rifampin
Intervention Trials
Tuberculosis 50
Tuberculosis, Pulmonary 19
Infections 9
Infection 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Isoniazid; Rifampin

Trials by Country

Trials by Country for Isoniazid; Rifampin
Location Trials
United States 141
China 40
Canada 22
South Africa 19
Brazil 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Isoniazid; Rifampin
Location Trials
California 13
New York 13
Texas 11
Illinois 9
Maryland 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Isoniazid; Rifampin

Clinical Trial Phase

Clinical Trial Phase for Isoniazid; Rifampin
Clinical Trial Phase Trials
Phase 4 11
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Isoniazid; Rifampin
Clinical Trial Phase Trials
Completed 31
Not yet recruiting 6
Recruiting 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Isoniazid; Rifampin

Sponsor Name

Sponsor Name for Isoniazid; Rifampin
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 10
Centers for Disease Control and Prevention 10
National Taiwan University Hospital 4
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Isoniazid; Rifampin
Sponsor Trials
Other 126
U.S. Fed 16
Industry 12
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Isoniazid and Rifampin

Introduction to Isoniazid and Rifampin

Isoniazid and rifampin are two of the most critical drugs in the treatment of tuberculosis (TB), a global health issue affecting millions. Here, we will delve into the latest clinical trials, market analysis, and projections for these essential anti-TB medications.

Clinical Trials Update

Isoniazid and Rifampin in Latent TB Infection (LTBI)

Clinical trials have consistently shown that rifampin regimens offer several advantages over traditional isoniazid regimens for treating LTBI. A retrospective study published in the Archives of Internal Medicine found that a 4-month rifampin regimen had higher treatment completion rates (71.6% vs 52.6%) and lower toxicity compared to a 9-month isoniazid regimen[1][5].

Rifamycin-Based Regimens

The CDC recommends rifamycin-based regimens, including 3 months of once-weekly isoniazid plus rifapentine, 4 months of daily rifampin, and 3 months of daily isoniazid plus rifampin, due to their effectiveness, safety, and high treatment completion rates[4].

New Drug Regimens

The TB Alliance has been conducting several clinical trials to evaluate new and potentially shorter drug regimens. For example, the SimpliciTB trial is testing the BPaMZ regimen (bedaquiline, pretomanid, moxifloxacin, and pyrazinamide) for patients with drug-sensitive (DS) and multidrug-resistant (MDR) TB. This regimen is administered for four months for DS-TB and six months for MDR-TB or mono-resistance to rifampicin or isoniazid[3].

Other Notable Trials

  • The REMoxTB trial tested whether substituting moxifloxacin for a single drug in the standard TB therapy could reduce treatment duration for drug-sensitive disease from six months to four[3].
  • The Nix-TB trial, which tested the BPaL regimen (bedaquiline, pretomanid, and linezolid), showed a favorable outcome in 90% of patients with XDR-TB or treatment-intolerant MDR-TB at six months after treatment[3].

Market Analysis

Market Size and Growth

The anti-tuberculosis therapeutics market is expected to grow at a CAGR of 6.2% by 2027, driven by rising initiatives from government organizations for TB awareness and the increasing prevalence of TB[2].

Isoniazid Segment

Isoniazid is anticipated to register a high CAGR in the anti-tuberculosis therapeutics market. This growth is attributed to the rising prevalence of TB and the adoption of isoniazid in combination with other drugs for treating TB. For instance, high-dose isoniazid has shown early bactericidal activity for Mycobacterium tuberculosis strains with inhA mutations, making it a valuable addition to second-line TB therapy regimens[2].

Rifampin Segment

Rifampin, another key player in TB treatment, is also expected to see significant growth. The preference for rifamycin-based regimens due to their higher treatment completion rates and lower toxicity will continue to drive the demand for rifampin[1][4].

Market Drivers

Rising Prevalence of Tuberculosis

The increasing incidence of TB, particularly in developing countries, is a major driver for the anti-tuberculosis drugs market. This rise is compounded by the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases[2].

Government Initiatives

Government organizations and global health bodies are increasing their efforts to raise awareness and improve treatment access for TB. These initiatives include the development and implementation of new treatment regimens and the promotion of existing effective treatments like rifampin and isoniazid[2].

Market Restraints

Adverse Side Effects

One of the significant restraints for the anti-tuberculosis drugs market is the adverse side effects associated with these medications. Isoniazid, in particular, is known for its hepatotoxicity, which can lead to treatment discontinuation[1][2].

High Cost of MDR and XDR TB Drugs

The high cost of drugs for treating MDR and XDR TB is another restraint. Newer regimens, while effective, can be expensive, making them less accessible in resource-poor settings[2].

Projections and Future Outlook

Increasing Adoption of Shorter Regimens

The trend towards shorter treatment regimens, such as the 4-month rifampin regimen, is expected to continue. These regimens offer better compliance and lower toxicity, which will drive their adoption in both developed and developing countries[1][4].

Innovations in Drug Formulations

The development of child-friendly formulations and fixed-dose combinations, such as the rifapentine and isoniazid combination, will simplify treatment regimens and reduce the pill burden, further boosting market growth[2][3].

Emerging Markets

Countries with high TB burdens, such as Ethiopia, Ghana, Kenya, Mozambique, and Zimbabwe, are piloting new short-course treatment regimens. These initiatives will expand the market for anti-tuberculosis drugs, including isoniazid and rifampin[2].

Key Takeaways

  • Clinical Trials: Rifampin regimens show higher treatment completion rates and lower toxicity compared to traditional isoniazid regimens for LTBI.
  • Market Growth: The anti-tuberculosis therapeutics market is expected to grow at a CAGR of 6.2% by 2027, driven by rising TB prevalence and government initiatives.
  • Isoniazid Segment: Expected to register high CAGR due to its adoption in combination therapies and high-dose regimens for MDR-TB.
  • Rifampin Segment: Preferred due to higher treatment completion rates and lower toxicity.
  • Market Drivers: Rising TB prevalence, government initiatives, and innovations in drug formulations.
  • Market Restraints: Adverse side effects and high costs of MDR and XDR TB drugs.

FAQs

Q1: What are the main differences between isoniazid and rifampin in treating latent TB infection?

A1: Rifampin regimens have higher treatment completion rates and lower toxicity compared to traditional 9-month isoniazid regimens. Rifampin is typically administered for 4 months, while isoniazid is given for 9 months[1][5].

Q2: How is the market for anti-tuberculosis drugs expected to grow?

A2: The market is expected to grow at a CAGR of 6.2% by 2027, driven by rising TB prevalence and government initiatives for TB awareness[2].

Q3: What are some of the new drug regimens being tested for TB treatment?

A3: New regimens include the BPaMZ regimen (bedaquiline, pretomanid, moxifloxacin, and pyrazinamide) and the BPaL regimen (bedaquiline, pretomanid, and linezolid) for drug-sensitive and multidrug-resistant TB[3].

Q4: What are the main restraints for the anti-tuberculosis drugs market?

A4: The main restraints are adverse side effects associated with these medications, particularly hepatotoxicity from isoniazid, and the high cost of drugs for treating MDR and XDR TB[1][2].

Q5: How are government initiatives impacting the market for anti-tuberculosis drugs?

A5: Government initiatives are increasing awareness and improving treatment access. They are also promoting the development and implementation of new, more effective treatment regimens, which is driving market growth[2].

Sources

  1. Page KR, Sifakis F, Montes de Oca R, et al. Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis: A Retrospective Study. Arch Intern Med. 2006;166(17):1863–1870. doi:10.1001/archinte.166.17.1863
  2. Mordor Intelligence. Anti-tuberculosis Therapeutics Market Size & Share Analysis.
  3. TB Alliance. Trials - TB Alliance.
  4. CDC. Guidelines for the Treatment of Latent Tuberculosis Infection.
  5. Academic.oup.com. 4 Months of Rifampin Compared with 9 Months of Isoniazid for the Treatment of Latent Tuberculosis Infection.
Last updated: 2025-01-05

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.